Subcutaneous Furosemide**

A Major Advance in Heart Failure Treatment

Furosemide, the treatment of choice for fluid overload in heart failure, has previously only been available in oral and intravenous (IV) forms. For patients for whom oral medication was insufficient, IV administration in a clinical setting was the only choice.

Now, scPharmaceuticals is making furosemide available for the first time for subcutaneous use, dispensed with its sc2Wear™ Infusor.

The company’s proprietary furosemide formulation has been optimized for use with the sc2Wear™ Infusor. Its pH has been reduced to a neutral level to minimize the risk of local irritation or discomfort.

UPDATE: On November 4, 2015, the company announced the pivotal trial results of its proprietary subcutaneous furosemide formulation in patients with heart failure. The results indicated that the subcutaneous administration of the novel furosemide formulation was as effective as the traditional intravenous administration in getting furosemide into the blood stream, and in achieving diuresis. Please click here to read the full release.


scPharmaceuticals’ furosemide formulation Furosemide injection, USP
Administration Subcutaneous Administration – 80mg by biphasic delivery Intravenous Administration – 2x 40mg IV at t0 and t2h
Bioavailability (t:0-24h) 100%* 100%
Diuresis 0-8 hours 2,654 mL 2,610 mL
Diuresis 0-24 hours 3,630 mL 3, 538 mL

Potential Benefits of Furosemide for Subcutaneous Delivery:

  • Greater flexibility as to where and by whom furosemide can be administered including healthcare providers, caregivers and patients
  • Avoidance of need for IV placement and potential complications, patient discomfort and infusion costs
  • Reduces cost of care by transitioning cost of delivery to a less expensive setting

Enhance Patient Care in a Wide Range of Situations

  • Reverse a Course of Deterioration: When oral alone is insufficient, subcutaneous furosemide may help to reverse worsening heart failure and prevent an ER visit or hospitalization.
  • Send a Patient Home Earlier: Diuresis takes time – the average patient loses more than 15 pounds during a standard 5-6 day hospital stay.   Some patients may be sent home several days earlier with use of subcutaneous furosemide.
  • Treat after Discharge: Research suggests that many patients despite feeling better still have considerable fluid overload upon discharge.   Some patients may benefit from additional days of outpatient or home treatment to achieve their treatment target and reduce the risk of readmission.
  • Increase Patient Comfort: Vascular access (placing an IV) may be difficult, time consuming and painful for some patients. Subcutaneous administration eliminates the need for IV. This may be of particular importance in end-of-life / hospice care situations.
  • Augment a Chronic Care Regimen: For some patients, oral furosemide alone is in not enough. These patients slowly retain water and salt and subcutaneous furosemide may help prevent further fluid build-up.

**CAUTION: Investigational Product – Limited by Federal Law to Investigational Use.